Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system

Antimicrob Agents Chemother. 2005 Feb;49(2):853-6. doi: 10.1128/AAC.49.2.853-856.2005.

Abstract

To study the efficacy of moxifloxacin treatment for tuberculosis, we utilized a novel cartridge system to simulate in vivo pharmacokinetics. We found this system to be a robust method for modeling in vivo pharmacokinetics and present data supporting the utility of intermittent moxifloxacin treatment as a component of antituberculosis chemotherapy.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Algorithms
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / pharmacokinetics
  • Anti-Bacterial Agents / therapeutic use*
  • Aza Compounds / administration & dosage
  • Aza Compounds / pharmacokinetics
  • Aza Compounds / therapeutic use*
  • Colony Count, Microbial
  • Computer Simulation
  • Fluoroquinolones
  • Half-Life
  • Infusion Pumps
  • Models, Biological
  • Moxifloxacin
  • Quinolines / administration & dosage
  • Quinolines / pharmacokinetics
  • Quinolines / therapeutic use*
  • Tuberculosis / drug therapy*
  • Tuberculosis / microbiology

Substances

  • Anti-Bacterial Agents
  • Aza Compounds
  • Fluoroquinolones
  • Quinolines
  • Moxifloxacin